{
    "id": 27370,
    "fullName": "ERBB3 V855A",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ERBB3 (HER3) V855A lies within the activation loop of the Erbb3 (Her3) protein (PMID: 26689995). V855A confers a gain of function to Erbb3 (Her3), as indicated by increased NRG1-beta induced cell growth in the presence of wild-type ERBB2 (HER2), increased interaction with ERBB2 (HER2), and increased ERBB2 (HER2) trans-phosphorylation in cell culture (PMID: 26689995).",
            "references": [
                {
                    "id": 9926,
                    "pubMedId": 26689995,
                    "title": "Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26689995"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2065,
        "geneSymbol": "ERBB3",
        "terms": [
            "ERBB3",
            "c-erbB-3",
            "c-erbB3",
            "ErbB-3",
            "erbB3-S",
            "FERLK",
            "HER3",
            "LCCS2",
            "MDA-BF-1",
            "p180-ErbB3",
            "p45-sErbB3",
            "p85-sErbB3"
        ]
    },
    "variant": "V855A",
    "createDate": "01/04/2018",
    "updateDate": "01/04/2018",
    "referenceTranscriptCoordinates": {
        "id": 123528,
        "transcript": "NM_001982",
        "gDna": "chr12:g.56097888T>C",
        "cDna": "c.2564T>C",
        "protein": "p.V855A",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12663,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) inhibited growth of cells transfected with ERBB3 (HER3) V855A and wild-type ERBB2 (HER2) in the presence of NRG1-beta in culture, however, was less effective than other ERBB (HER) inhibitors (PMID: 26689995).",
            "molecularProfile": {
                "id": 28812,
                "profileName": "ERBB2 wild-type ERBB3 V855A"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9926,
                    "pubMedId": 26689995,
                    "title": "Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26689995"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12662,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Perjeta (pertuzumab) inhibited growth and NRG1-beta induced ERBB3 (HER3) and ERBB2 (HER2) phosphorylation in cells transfected with ERBB3 (HER3) V855A and wild-type ERBB2 (HER2) in culture (PMID: 26689995).",
            "molecularProfile": {
                "id": 28812,
                "profileName": "ERBB2 wild-type ERBB3 V855A"
            },
            "therapy": {
                "id": 856,
                "therapyName": "Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9926,
                    "pubMedId": 26689995,
                    "title": "Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26689995"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12661,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited growth and NRG1-beta induced ERBB3 (HER3), ERBB2 (HER2), and AKT phosphorylation, and increased apoptosis of cells transfected with ERBB3 (HER3) V855A and wild-type ERBB2 (HER2) in culture (PMID: 26689995).",
            "molecularProfile": {
                "id": 28812,
                "profileName": "ERBB2 wild-type ERBB3 V855A"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9926,
                    "pubMedId": 26689995,
                    "title": "Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26689995"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28811,
            "profileName": "ERBB3 V855A",
            "profileTreatmentApproaches": [
                {
                    "id": 16659,
                    "name": "HER3 Inhibitor",
                    "profileName": "ERBB3 V855A"
                },
                {
                    "id": 16657,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "ERBB3 V855A"
                },
                {
                    "id": 16658,
                    "name": "HER2 Inhibitor",
                    "profileName": "ERBB3 V855A"
                }
            ]
        },
        {
            "id": 28812,
            "profileName": "ERBB2 wild-type ERBB3 V855A",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 123528,
            "transcript": "NM_001982",
            "gDna": "chr12:g.56097888T>C",
            "cDna": "c.2564T>C",
            "protein": "p.V855A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}